AG
NVLN

Advisor Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Advisor Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed – – 5554
2019
Q2 		$0 Buy
+100
New +$111 ﹤0.01% 5496
2017
Q4 		– Sell
-594
Closed -$4K – 5153
2017
Q3 		$4K Hold
594
– – ﹤0.01% 4393
2017
Q2 		$5K Hold
594
– – ﹤0.01% 4271
2017
Q1 		$6K Hold
594
– – ﹤0.01% 4072
2016
Q4 		$5K Buy
+594
New +$5.26K ﹤0.01% 3970

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Advisor Group's NVLN Position: Q3 2019 in Review

Advisor Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2019, closing a stake of 100 shares.

Advisor Group first reported a position in NVLN in Q4 2016 and held it in 5 quarters. The position peaked at $6K in Q1 2017. 31 funds tracked by Wall St. Rank hold NVLN as of Q3 2019.

  • Advisor Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2019 after selling out during the quarter.
  • Advisor Group sold 100 Novelion Therapeutics Inc. Common Shares shares in Q3 2019.
  • Advisor Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 5 quarters.
  • Advisor Group's Novelion Therapeutics Inc. Common Shares position peaked at $6K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2019.

Based on Advisor Group's 13F filing for Q3 2019, filed 13 Nov 2019.